Summit Therapeutics

ASCO
Favicon Fierce Pharma

Akeso's 34% overall survival win comes with caveats

While ivonescimab and chemo's 34% improvement on overall survival exceeded expectations, detailed data from Harmoni-6 are being picked apart.
Angus Liu May 31, 2026 8:00am
Graphic of a fork in the road with arrows pointing in either direction

ASCO: BioNTech/BMS, Pfizer split on bispecific approach in NSCLC

May 30, 2026 3:30pm
Stock market drop
Favicon Fierce Pharma

Summit shares tumble on interim PD-1/VEGF trial miss

May 1, 2026 10:56am
merck

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

Apr 17, 2026 3:00pm
Pfizer

Pfizer lays out its PD-1xVEGF bispecific research strategy

Nov 11, 2025 11:43am
Akeso
Favicon Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am